Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with ...
Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...
With the Biden administration pushing for Medicare, Medicaid coverage of GLP-1s, analysts disagree on whether it will ...
The term "nonalcoholic fatty liver disease" (NAFLD) has long been used to describe liver steatosis not related to excessive alcohol consumption ...
Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...
Tv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 22,500 shares, a decrease ...
GLP-1 drugs are quickly becoming some of the most ubiquitous in the U.S., and they have drawn interest for their potential ...
Health on MSN1d
Study Finds Nearly Half of People on Obesity Drugs Drink Less—But Do Scientists Know Why?New research found that some anti-obesity medications such as Wegovy and Zepbound may prompt people to drink less. These ...
1d
Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...
But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...
GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback